BeStock  
Stocks › Biotechnology › AVTX

Avalo Therapeutics AVTX

US equityMarket cap rank #3681Biotechnology
$6.76 +$0.01 (+0.15%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $6.76 0.00%
Open$6.65
Prev close$6.75
Day range$6.61 – $7.03
Volume1.18M
Market cap$390.88M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership119.5%-17.71 pts vs. prior quarter
Institutions holding173+22 vs. prior quarter
Insider trades (recent)20 buys / 30 sellsNet selling
Short interest16.62% of floatDays to cover 2.1 · as of 30 Oct 2026
Short-sale volume share18.7%5-day average of daily volume

Short-sale volume as % of daily volume

4%12%21%29%Oct '26Oct '26Nov '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$1.46M (10 inflow days, 10 outflow days).

Net flow by order size, last 20 sessions

−$2.5MSuper+$1.0MBig−$160.0KMid−$123.1KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 36.2% of shares outstanding.

Largest holders

  • FMR10.70%
  • BlackRock8.58%
  • Deep Track Capital, LP6.24%
  • Caligan Partners, LP5.47%
  • TCG Crossover Management, LLC5.22%
  • Affinity Asset Advisors, LLC5.02%
  • Trails Edge Capital Partners, LP4.85%
  • State Street Global Advisors4.43%

By investor type

  • Hedge Fund61.39%
  • Mutual Fund33.68%
  • VC/PE Fund17.27%
  • Public Company5.38%
  • Individual/Insider1.43%
  • Sovereign Wealth Fund0.78%
  • Private Company0.72%
  • Insurance Company0.15%

Reported short interest has fallen from 24.41% to 16.62% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Trails Edge Capital Partners, LP Hedge Fund 2026/Q3 +1,911,880 4.8%
BlackRock Mutual Fund 2026/Q3 +594,051 8.6%
BlackRock Mutual Fund 2026/Q3 +4,038,471 8.1%
Deep Track Capital, LP VC/PE Fund 2026/Q3 +3,610,000 6.2%
State Street Global Advisors Mutual Fund 2026/Q3 +2,817,633 5.4%
TCG Crossover Management, LLC VC/PE Fund 2026/Q3 +2,278,737 5.2%
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +1,782,926 4.8%
Braidwell LP Hedge Fund 2026/Q3 +1,629,182 2.8%
Farallon Capital Management, L.L.C. Hedge Fund 2026/Q3 +1,582,000 4.3%
Affinity Asset Advisors, LLC Hedge Fund 2026/Q3 +1,559,160 5.0%
Caligan Partners, LP Hedge Fund 2026/Q3 +1,528,843 5.5%
Point72 Asset Management, L.P. Hedge Fund 2026/Q3 +1,470,884 4.1%
Bank of America Corporation Public Company 2026/Q3 +1,270,829 3.3%
AllianceBernstein Mutual Fund 2026/Q3 +1,260,689 2.4%
Soleus Capital Management, L.P. Hedge Fund 2026/Q3 +1,213,000 2.9%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
29 Sep 2026 Kevin Lind Independent Director Other Derivative Acquisition +1,352 $15.33 1,352
29 Sep 2026 Rita Jain Independent Director Other Derivative Acquisition +1,322 $15.33 1,322
29 Sep 2026 Ron Philip Independent Director Other Derivative Acquisition +1,109 $15.33 1,109
15 Sep 2026 Christopher Sullivan CFO & Head of Investor relations Derivative Exercise and Sale -12,394 $16.33 39,900
9 Sep 2026 Christopher Sullivan CFO & Head of Investor relations Derivative Exercise and Sale -10,185 $17.62 39,900
27 Aug 2026 Mittie Doyle Chief Medical Officer Derivative Exercise and Sale -679 $20.00 8,276
17 Aug 2026 Christopher Sullivan CFO & Head of Investor relations Derivative Exercise and Sale -71,852 $20.05 –
16 Aug 2026 Mittie Doyle Chief Medical Officer Derivative Exercise and Sale -1,000 $20.00 8,276
16 Aug 2026 Christopher Sullivan CFO & Head of Investor relations Open Market Disposition -873 $19.94 –
10 Aug 2026 Jennifer Riley Chief Strategy Officer Open Market Disposition -2,655 $19.59 2,841
9 Aug 2026 Mittie Doyle Chief Medical Officer Derivative Exercise and Sale -679 $20.00 8,276
26 Jul 2026 Mittie Doyle Chief Medical Officer Derivative Exercise and Sale -1,000 $20.00 8,276
29 Jun 2026 Kevin Lind Independent Director Other Derivative Acquisition +1,105 $18.48 1,105
29 Jun 2026 Mittie Doyle Chief Medical Officer Derivative Exercise and Sale -4,654 $20.00 8,276
29 Jun 2026 Rita Jain Independent Director Other Derivative Acquisition +1,080 $18.48 1,080
29 Jun 2026 Ron Philip Independent Director Other Derivative Acquisition +69 $18.48 69
22 Jun 2026 Mittie Doyle Chief Medical Officer Derivative Exercise and Sale -1,450 $18.00 8,276
22 Jun 2026 Ron Philip Independent Director Other Derivative Acquisition +40,200 $17.83 40,200
9 Jun 2026 Mittie Doyle Chief Medical Officer Sale to Issuer -1,084 $13.10 8,276
9 Jun 2026 Paul Varki Chief Legal Officer Sale to Issuer -1,081 $13.10 8,276

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
30 Oct 2026 8,910,655 16.6% 2.1
15 Oct 2026 11,963,625 22.3% 13.0
30 Sep 2026 11,405,304 21.3% 8.8
15 Sep 2026 12,925,869 24.1% 13.2
31 Aug 2026 12,387,012 23.1% 15.2
14 Aug 2026 13,092,767 24.4% 20.2

Discussion

No comments yet — be the first to weigh in on AVTX.

Sign in to join the discussion.

Scroll to Top